Buzdar A U, Legha S S, Tashima C K, Hortobagyi G N, Yap H Y, Krutchik A N, Luna M A, Blumenschein G R
Cancer Treat Rep. 1978 Jul;62(7):1005-8.
Ninety-one patients with advanced breast cancer failing adriamycin (ADR)-containing combination chemotherapy were treated with a combination of mitomycin C (MMC) and megestrol acetate. Congestive heart failure (CHF) occurred in 14 (15.3%) of 91 MMC-treated patients compared to three (3.4%) of 89 patients treated with similar ADR-containing combination chemotherapy without MMC (P = 0.01). The median time from the last dose of ADR to evidence of CHF was 8.5 months for the MMC group compared to 1.5 months for the other group. A significantly higher incidence of late onset of CHF implicates MMC as a possible cardiotoxic agent.
91例含阿霉素（ADR）联合化疗失败的晚期乳腺癌患者接受了丝裂霉素C（MMC）和醋酸甲地孕酮联合治疗。91例接受MMC治疗的患者中有14例（15.3%）发生充血性心力衰竭（CHF），而89例接受不含MMC的类似含ADR联合化疗的患者中有3例（3.4%）发生CHF（P = 0.01）。MMC组从最后一剂ADR至出现CHF的中位时间为8.5个月，而另一组为1.5个月。CHF迟发的发生率显著更高，提示MMC可能是一种心脏毒性药物。
